Inhibition of insulin/IGF‐1 receptor signaling protects from mitochondria‐mediated kidney failure. Issue 3 (2nd February 2015)

• Record Type: Journal Article
• Authors: Ising, Christina; Koehler, Sybille; Brähler, Sebastian; Merkwirth, Carsten; Höhne, Martin; Baris, Olivier R; Hagmann, Henning; Kann, Martin; Fabretti, Francesca; Dafinger, Claudia; Bloch, Wilhelm; Schermer, Bernhard; Linkermann, Andreas; Brüning, Jens C; Kurschat, Christine E; Müller, Roman‐Ulrich; Wiesner, Rudolf J; Langer, Thomas; Benzing, Thomas; Brinkkoetter, Paul Thomas
• Is Part Of: EMBO molecular medicine. Volume 7:Issue 3(2015:Mar.)
• Page Start: 275
• Page End: 287
• Publication Date: 2015-02-02
• Subjects: Molecular biology -- Periodicals; Medical genetics -- Periodicals; Pathology, Molecular -- Periodicals; 616.04205
• DOI: 10.15252/emmm.201404916
• Languages: English
• ISSNs: 1757-4676

Abstract

<abstract abstract-type="graphical" xml:lang="en" id="emmm201404916-abs-0003"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Podocyte‐specific PHB2 loss results in severe kidney disease that is alleviated by insulin and IGF‐1 receptors deletion or rapamycin treatment, demonstrating not only a causal link between mitochondrial dysfunction and kidney disease but also putative therapeutic avenues. <boxed-text content-type="graphic" id="emmm201404916-blkfxd-0002" position="anchor" orientation="portrait"><graphic position="anchor" mimetype="image" xlink:href="ark:/27927/pgj5jh7m93" orientation="portrait" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink" /></boxed-text></p> </abstract>